Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic • ASCO 2023
What are your top takeaways in Breast Cancer from ASCO 2023?
Answer from: Medical Oncologist at Community Practice
SONIA: A notable trial comparing CDK4/6 inhibitors as 1st line vs. 2nd line treatment. AI+CDKi combination therapy as 1st line does not improve OS, 2nd PFS, or QOL compared to combination therapy as 2nd line. Factors such as the site of metastasis, tumor burden, symptoms, cost, and side effects sh...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NATALEE - Adjuvant Ribociclib study. Will be nice to be able to offer CDK4/6 inhibitors in high risk node negative patients as well as node positive.
SONIA trial - showed that there was no difference in benefit whether CDK4/6 is offered in first or second line was provocative
X-7/7 study -...
Answer from: Radiation Oncologist at Academic Institution
The 2023 ASCO meeting did not contain much of general importance this year in my view, compared to last year's meeting. Only two abstracts stood out to me.
Abstract 503: Gray RG et al., Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis ...
Comments
Radiation Oncologist at West Virginia University
Not sure how many phase 3 trials will we need befo...
Not sure how many phase 3 trials will we need befo...
Answer from: Medical Oncologist at Academic Institution
NATALEE is important. However, the conclusion that ribociclib for 3 years in the high-risk adjuvant setting is similar to that of abemaciclib has limited impact. The median follow-up is too short given the length of treatment.